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ABSTRACT
Vaults are ribonucleoprotein particles with a distinct structure and a
high degree of conservation between species. Although no function has
been assigned to the complex yet, there is some evidence for a role of vaults
in multidrug resistance. To confirm a direct relation between vaults and
multidrug resistance, and to investigate other possible functions of vaults,
we have generated a major vault protein (MVP/lung resistance-related
protein) knockout mouse model. The MVP/ mice are viable, healthy,
and show no obvious abnormalities. We investigated the sensitivity of
MVP/ embryonic stem cells and bone marrow cells derived from the
MVP-deficient mice to various cytostatic agents with different mecha-
nisms of action. Neither the MVP/ embryonic stem cells nor the
MVP/ bone marrow cells showed an increased sensitivity to any of the
drugs examined, as compared with wild-type cells. Furthermore, the
activities of the ABC-transporters P-glycoprotein, multidrug resistance-
associated protein and breast cancer resistance protein were unaltered on
MVP deletion in these cells. In addition, MVP wild-type and deficient mice
were treated with the anthracycline doxorubicin. Both groups of mice
responded similarly to the doxorubicin treatment. Our results suggest that
MVP/vaults are not directly involved in the resistance to cytostatic agents.
INTRODUCTION
The 13 megadalton mammalian vault complex is the largest ribo-
nucleoprotein particle described to date (1). Vaults are predominantly
found in the cytoplasm; however, a small percentage of vaults seems
to be associated with the nucleus, in particular the nuclear membrane
and nuclear pore complex (2–4). Some groups have shown a partial
association of vaults with cytoskeletal elements (4, 5). Although the
function of vaults remains to be elucidated, the subcellular localiza-
tion of the complex as well as the distinctive shape, a conserved
hollow barrel-like structure with an invaginated waist and two pro-
truding caps (6), has led to the hypothesis that vaults function in
cellular transport (7) and/or nucleo-cytoplasmic transport (2–4).
Many reports point to a role for vaults in cellular defense against
toxic compounds and consequently in MDR.3 Relatively high vault
levels have been found in tissues that are frequently exposed to
xenobiotic elements, such as epithelia of the gastrointestinal tract and
lung. Furthermore, the expression of the MVP, also referred to as
LRP, was associated with a non-P-gp-mediated multidrug resistant
phenotype in human cancer cell lines (8–11). In addition, MVP
expression closely reflected known chemoresistance characteristics in
broad panels of unselected tumor cell lines and untreated clinical
cancers of different histogenetic origins (8, 12). Several clinical
studies indicate that expression of MVP is associated with a poor
response to chemotherapy, but other studies have failed to show a
correlation between MVP expression and clinical drug resistance
(reviewed in Ref. 13). Direct evidence for the involvement of vaults
in drug resistance was presented by Kitazono et al. (14, 15). They
showed that increased levels of MVP in the colon carcinoma SW620
cells paralleled increased resistance to doxorubicin, etoposide, and
Taxol. This resistance could be partly overcome by expression of
MVP-specific ribozymes. However, expression of MVP, stably trans-
fected in the ovarian carcinoma cell line A2780, leads to increased
numbers of vault particles, but does not confer a drug resistance
phenotype (16, 17).
Vaults consist of three proteins, a Mr 100,000 MVP, and two minor
vault proteins of Mr 193,000 (VPARP) and Mr 240,000 (TEP1), as
well as many copies of a small untranslated RNA (vRNA) of 88–141
bases. Interestingly, the TEP1 subunit is also associated with the
telomerase complex (18, 19). Within this complex, its function is
unknown, but it was shown that TEP1 binds to telomerase RNA.
However, the recently generated TEP1 knockout mice do not show
abnormalities in telomere length nor telomerase activity (20). In these
mice, vault-like particles were observed that appear structurally intact
but have a decreased density in the caps. It was found that TEP1 is
capable of binding vRNA, and is responsible for the stabilization of
vRNA and its binding to vaults (21). VPARP contains a functional
PARP domain. Several proteins with such a domain have been iden-
tified; PARP1, the best-studied protein of this group, has been shown
to play a role in base excision repair. Also, other proteins with PARP
activity might be involved in DNA damage repair and genomic
stability (reviewed in Ref. 22). Other than its association with the
vault complex, VPARP is also located in the nucleus, which might
point to an involvement in DNA damage repair as well. VPARP has
been shown to ADP-ribosylate itself and MVP (23). The identification
of other substrates of VPARP might give insight in the function of
VPARP and/or the vault complex. However, the bulk of the vault
complex is made up by the MVP. Expression of MVP in insect cells
that do not express VPARP and TEP1 gives rise to vault-like particles
(24), a finding that illustrates the importance of the MVP in the
formation of the vault complex. Therefore, absence of MVP will most
likely result in a disruption of the whole vault particle and, hence,
eliminate or severely impair its function.
Here we describe the generation of a MVP-deficient mouse model.
We revealed previously the genomic organization of the murine MVP
gene (25), which enabled us to construct a targeting vector that was
used to disrupt one allele of the MVP gene. Subsequently, we gener-
ated MVP-deficient mice that were studied extensively for any phys-
ical abnormalities. To investigate the potential role of vaults in the
cellular resistance to chemotherapy, several in vitro drug sensitivity
assays were performed using cells and cell lines derived from the
MVP knockout model. In addition, the in vivo toxicity of doxorubicin
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was tested in wild-type and knockout mice to examine the effect of
MVP absence on the systemic protection against chemotherapy.
MATERIALS AND METHODS
Generation of the Targeting Construct and MVP-deficient ES Cells
The MVP gene was isolated from genomic E14 DNA and mapped as
described (25). By Southern blot analysis and DNA sequencing the intron-exon
structure was determined. The targeting construct consisted of two genomic
fragments, a 2.6-kb BalI-TthIII1 fragment containing intron 3 and part of exon
4, and a 5-kb EcoRI-SalI fragment containing exons 8, 9, and 10. These
fragments were cloned into pBS-KSII (Stratagene, La Jolla, CA). Between the
two homologous arms we placed a phosphoglycerate kinase-driven neomycin
cassette, in antisense direction with respect to the MVP transcription. To
facilitate the screen for ES cells that underwent homologous recombination,
the construct was flanked by the negative selection marker herpes simplex
virus-thymidine kinase (see Fig. 1A). Before electroporation of the ES cells,
the vector was linearized by digestion with NotI. The culturing and manipu-
lation of ES cells were performed essentially as previously described (26). In
short, a total of 12  106 E14 ES cells, derived from a 129/Ola background,
were mixed with 25 g of linearized target vector and electroporated with a
pulse of 117 volt and 1200 F for 10 ms. After a 10-min incubation at room
temperature, the cells were plated in 10-cm2 dishes and incubated at 37°C, 5%
CO2. The following day, the cells were divided over eight dishes, and incu-
bated in G418 and ganciclovir containing medium (300 g/ml and 100 g/ml,
respectively). The clones surviving this selection were isolated, expanded in
24-well plates, and genotyped by Southern blot analysis of BamHI-digested
DNA, using a 300-bp probe located just upstream of exon 3 (Fig. 1A).
For experimental purposes, the remaining intact MVP allele was also
disrupted using the same targeting construct but with the neomycin cassette
replaced by a hygromycin cassette. Double-targeted ES cells were initially
selected on a medium containing hygromycin only (100 g/ml) and later
examined for disruption of both MVP alleles using the 300-bp probe mentioned
above.
Generation and Genotyping of MVP Knockout Mice
Chimeric mice were generated by injecting the manipulated 129/Ola-
derived, MVP/ ES cells into C57BL/6 blastocysts as described (26). Het-
erozygous offspring of the chimeric mice was used to generate MVP-deficient
(MVP/), heterozygous (MVP/), and wild-type (MVP/) animals. Two
sets of primers were used to genotype the mice by PCR on DNA isolated from
tails. One primer set specific for the wild-type allele (forward 5-GGCTG-
GTCCGATCCGTCGGTCCTTATCTCCC and reverse 5-CAGTAGTGTC-
GAGGTCCCAGGGTGGTGATG) results in a 520-bp fragment spanning ex-
ons 6 and 7. The second primer set amplifies a 200-bp fragment of the
neomycin cassette (forward 5-TACTCGGATGGAAGCCGGTC and reverse
5-AGTCGATGAATCCAGAAAAG). PCR conditions were: 10 min 94°C,
followed by 30 cycles of 1 min 94°C, 1 min 65°C, and 1 min 72°C, followed
by 10 min at 72°C. The PCR strategy was validated by comparing the results
from a Southern blot analysis with the PCR-based data (data not shown). All
of the animals used in this study were of a mixed genetic background of
129/Ola and C57BL/6 strains, backcrossed for one to four generations to
C57BL/6. Littermate wild-type animals were used as controls, except in the in
vivo doxorubicin experiment, where the large numbers of animals included
restricted the use of controls exclusively consisting of littermates. In this
experiment the groups were composed of animals from several litters matched
for age and sex, and all derived from fourth-generation backcrosses with
C57BL/6.
Western and Northern Blot Analysis
Tissues from MVP/, MVP/, and MVP/ littermate animals were
homogenized in a 10 mM sodium phosphate buffer (pH 7.4) containing 0.25%
(v/v) Triton X-100 and proteinase inhibitors, using an Ultra-Turrax T25
(IKA-Labortechnik). The tissue lysates were spun briefly to pellet insoluble
material. Protein concentrations were determined by the bicinchoninic acid
method (Pierce, Rockford, IL). MVP was detected using a polyclonal antibody
raised against human MVP (9) and the enhanced chemiluminescence detection
system (Amersham-Pharmacia, Uppsala, Sweden).
Total RNA was purified from MVP/, MVP/, and MVP/ littermate
animals using RNAzol (Campro Scientific, Berlin, Germany) following the
recommendations of the manufacturer. Ten g of total RNA was subjected to
formaldehyde-agarose gel electrophoresis as described (27). Subsequently the
size-fractionated RNA was blotted onto Hybond-N filters (Amersham, Little
Chalfont, United Kingdom). ULTRAhyb (Ambion, Austin, TX) was used as
blocking and hybridization mix according to the recommendations of the
manufacturer. The blot was probed overnight with an in vitro transcribed
antisense [32P]-labeled MVP RNA probe, at 68°C, and subsequently washed
for 2  5 min in 2  SSC, 0.1% SDS and 2  15 min in 0.1  SSC, 0.1%
SDS at 68°C. As a loading control, afterward the same blot was probed with
a radiolabeled 18 S rRNA oligonucleotide probe (5-CTTTCGCTCTGGTC-
CGTCTTGCGCCGGTCC).
Vault Purification and Analysis
Vaults were purified from mouse livers as described previously (6), using a
protocol adapted to the limited quantities and size of the mouse livers (21).
Electron microscopy of uranyl acetate-stained vaults was carried out as de-
scribed (28).
Isolation of Immature Bone Marrow Cells
Femurs and tibia were isolated from MVP/ and MVP/ littermates. The
bones were cleaned and crushed in a sterile mortar to extract the cells using
HBSS with 5% FCS, penicillin (100 units/ml), and streptomycin (100 mg/ml).
The cells were filtered through a 100-mm cell strainer (Becton Dickinson,
Franklin Lakes, NJ) and spun down at 500  g for 10 min. The cell pellet was
resuspended in 50 ml of HBSS, and incubated at 37°C and 5% CO2 for 60 min.
To separate the immature proliferative cells from the more mature bone
Fig. 1. Strategy of MVP gene disruption. A, schematic presentation of the gene
targeting strategy, showing wild-type allele, targeting construct with the position of the
neomycin resistance and the thymidine kinase cassettes, and the recombinant allele after
gene disruption. The dotted line on top indicates the position of the probe used for
genotyping ES cell clones and mice. B, BamHI; S, SalI restriction enzyme sites. B,
Southern blot analysis of wild-type, targeted, and double-targeted ES cells. BamHI
digested genomic DNA was hybridized with the probe depicted in A. Hybridizing
fragments from wild-type (/) and MVP knockout (/) alleles are 9.8 kb and 3.2 kb,
respectively.
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marrow cells, the cells were harvested and resuspended in 300 ml of Ca2/
Mg2-free PBS, and mixed with 2.7 ml of a 55% Percoll (Amersham-
Pharmacia) solution. This mixture was loaded on a Percoll gradient, consisting
of 3 ml of 85%, 2 ml of 62%, and 2 ml of 55% Percoll in Ca2/Mg2-free
HBSS. The gradient was centrifuged for 30 min at 1650  g using slow
acceleration and no brakes. The upper fraction, containing the most immature
cells, was collected. To induce proliferation, the cells were prestimulated in
Cellgro medium (Boehringer, Heidelberg, Germany) containing 10 ng/ml
thrombopoietin (Genentech, South San Francisco, CA), 10 ng/ml granulocyte
macrophage colony-stimulating factor (R&D, Minneapolis, MN), 10 ng/ml
interleukin 3 (R&D), 100 ng/ml stem cell factor (Amgen, Thousand Oaks,
CA), and 50 ng/ml FLT3 (Immunex, Seattle, WA). After 2 days the cells were
harvested and used in proliferation assays. During the proliferation assays the
cells were cultured in medium containing the growth factors mentioned above.
Functional Tests for P-gp, MRP1, and BCRP
The activities of P-gp, MRP1, and BCRP were monitored by fluorescence-
activated cell sorter analysis. Three  105 wild-type and knockout ES cells or
immature bone marrow cells were incubated in DMEM with or without 2 mM
of the P-gp inhibitor PSC 833 (Novartis Pharma), 100 mM of the MRP1
inhibitor MK571 (Alexis, Lausen, Switzerland), or with 200 nM of the BCRP
modulator Ko143 (29). After a 30–60 min incubation at 37°C, 5% CO2, 200
ng/ml Rhodamine-123 (Sigma-Aldrich), 100 nM DCFDA (Sigma-Aldrich), or
100 nM BODIPY-prazosin (Molecular Probes Inc., Eugene, OR), substrates for
P-gp, MRP1, or BCRP, respectively, was added. The cells were incubated with
the substrates for an additional 75 min, after which the cells were mixed with
2 ml of ice-cold PBS supplemented with 0.1% sodium azide and spun at
650  g. Before analyzing the cells by fluorescence-activated cell sorter, 8 l
of 5 nM TOPRO-3 (Molecular Probes) was added. 8226S and the P-gp-
overexpressing derivative 8226D6 (30), GLC4 and the drug-resistant deriva-
tive expressing MRP1, and vaults GLC4-ADR (31) and MCF-7 and the
drug-resistant, BCRP-overexpressing cell line MCF-7 AdVp3000 (32) were
included as positive and negative controls for P-gp, MRP1, and BCRP func-
tion, respectively.
Analysis of Drug Sensitivity
Cell Survival Assay. The sensitivity to anticancer agents was tested in
MVP/ and MVP/ ES cells using a MTT microtiter plate assay (33). In
brief, on day 1, 3000 cells were seeded in 50 l medium/well on gelatin-
coated, flat-bottomed 96-well plates. After an incubation of 6 h at 37°C, 5%
CO2, drugs were added at various concentrations. After 3 days of incubation,
10 l of a 5 mg/ml MTT solution in 0.9% NaCl was added in each well, and
the incubation continued for an additional 6 h at 37°C, 5% CO2. The formazan
crystals produced by viable cells were resuspended by adding 100 l/well of
acidified isopropanol, after which the absorbance at 562 nm was measured on
a plate reader. At least 12 different drug concentrations were used to determine
IC50 values.
Cell Proliferation Assay. Proliferation of bone marrow cells from
MVP/ and MVP/ littermate mice was tested in a [3H]thymidine incorpo-
ration assay. For this purpose, immature bone marrow cells, isolated by a
Percoll gradient and prestimulated for 48 h, were seeded at a density of 20,000
cells/well in a microtiter plate in 100 l of medium containing growth factors
and incubated at 37°C, 5% CO2. Drugs were added 24 h later in various
concentrations, and the cells were incubated for an additional 8 h. Then
[3H]thymidine (25 Ci in 25 l medium) was added to each well, and the cells
were incubated overnight. Cells were transferred to a glass fiber filter using a
filtermate 196 cell harvester (Packard Bioscience, Groningen, The Nether-
lands), and the radioactivity on the filters was determined by a topcount
microplate scintillation counter (Packard Bioscience).
In Vivo Toxicity of Doxorubicin. Ten or 15 mg doxorubicin/kg body-
weight was administered to MVP knockout animals, and age- and sex-matched
wild-type animals by i.v. injection in the tail. The animals were examined daily
for signs of discomfort and illness. Body weights were determined daily, and
blood cell counts were performed on days 3 and 8 after injection. At day 5 after
injection, the animals that received the 10 mg/kg doxorubicin dose and PBS
injected controls were sacrificed and examined thoroughly for histopathologic
abnormalities using standard protocols.
RESULTS
MVP-deficient Mice Are Viable and Appear Normal. ES cell
clones surviving the selection medium were genotyped by digestion
with BamHI followed by Southern blot analysis. This resulted in a
9.8-kb and a 3.2-kb hybridizing fragment for the wild-type and
recombinant allele, respectively (Fig. 1B). A probe at the 5 end of the
construct was used to confirm the disruption of the MVP allele. The
presence of additional integrations was excluded by using a probe
based on the neomycin cassette (results not shown). Before the
MVP/ ES cells were injected into blastocysts, the number of
chromosomes present in metaphase spreads was counted to verify the
karyotype was stable.
Chimeric animals, resulting from blastocyst injection, were back-
crossed to C57BL/6 mice to obtain heterozygous animals. These
heterozygous mice were intercrossed to produce MVP/ and
MVP/ littermates. The genotype of the animals was determined by
Southern blot analysis and/or PCR on tail DNA (compare Fig. 1B).
The disruption of MVP was confirmed at RNA and protein level. A
Northern blot analysis on total RNA isolated from liver from wild-
type, heterozygous, and MVP-deficient animals demonstrated that no
MVP transcripts were detectable in the knockout tissue. Although the
loading was not completely equal, judged from the 18S rRNA signal,
a decreased signal was found in the heterozygous tissue when com-
pared with the normal tissue (Fig. 2A). On Western blot, the knockout
tissues contained no detectable MVP, and the heterozygous tissues
showed intermediate levels of protein expression (Fig. 2B). Similar
results were observed with other organs (data not shown).
To verify that the vault particle is indeed disrupted on the loss of
MVP, we biochemically fractionated wild-type and MVP knockout
mouse livers to purify vaults. In the final purification step, the vaults
were purified over a single cesium chloride gradient. Vaults were
recovered from gradient fractions by dilution and pelleting at
100,000  g, and analyzed by electron microscopy (Fig. 2C). The
typical barrel-shaped vault particles were clearly present in the wild-
type liver fractions but could not be detected in the corresponding
fractions obtained from MVP knockout livers. This indicates that
MVP cannot be substituted for by another protein, which is in agree-
ment with our previous findings that the murine genome contains a
single MVP gene (25).
The MVP knockout mice appeared viable, were born at Mendelian
ratios, bred normally, and did not show clear physical abnormalities
up to 16 months of age. Animals of different ages were histologically
examined, with special attention to tissues that normally express
relatively high levels of MVP/vaults (i.e., lung, liver, and gastroin-
testinal tract). No microscopical differences were observed between
knockout and wild-type littermates (data not shown). Also, no differ-
ences were observed in bone marrow and peripheral blood cell counts,
and in serum levels of glucose, blood urea, cholesterol, and creatine
(results not shown).
Drug Sensitivity in MVP-deficient Cells. A correlation between
vault expression and drug resistance has been shown in cell lines as
well as for primary human tumors. To examine whether vaults influ-
ence the cellular defense against drugs, we tested the sensitivity of ES
cells and immature bone marrow cells to various cytostatic agents.
Both ES and immature bone marrow cells were shown to express
MVP/vaults, whereas no MVP could be detected in MVP/ ES and
bone marrow cells derived from MVP/ mice (Fig. 3). The survival
of MVP/ ES cells in response to increasing concentrations of
cytostatic drugs was compared with the survival of the parental
MVP/ ES cells in a MTT assay. To determine the drug concentra-
tion IC50 value, 12 different concentrations of each drug were tested.
Although a broad range of drugs, exerting toxicity in different man-
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ners, was included, no statistically significant differences in IC50
values were observed between wild-type and knockout cells for any of
the cytostatics (Table 1). To investigate the effect of drugs on the
proliferative capacity of wild-type and knockout cells, we used im-
mature bone marrow cells, induced to proliferate in a [3H]thymidine
incorporation assay. The proliferation after a 24-h incubation with
increasing concentrations of cytostatic agents was expressed as a
percentage of the proliferation measured in untreated cells. The drug
concentrations at which the proliferation is decreased by 50% are
listed in Table 2. In all of the cases, the inhibition of cell proliferation
induced by the cytostatics appears unaltered in MVP-deficient cells.
To test whether the absence of MVP results in altered expression of
other multidrug resistance-related proteins such as P-gp, MRP1, and
BCRP, the activities of these membrane pumps were examined in
wild-type and knockout ES cell lines and bone marrow cells. For this
purpose, we measured the intracellular retention of fluorescent sub-
strates in the presence or absence of P-gp, MRP1, and BCRP modu-
lators by flow cytometry. The ratio of substrate retained in the cell in
the presence and absence of their modulators is a measure of the
activity of these membrane pumps. Table 3 summarizes the activities
of the three proteins on ES cells and immature bone marrow cells.
Both ES cells and bone marrow cells appear to exhibit a low activity
of P-gp and BCRP, whereas addition of the MRP1 modulator MK571
clearly increased the intracellular amount of fluorescent substrate,
indicating that MRP1 is functionally present on the surfaces of these
cells (Fig. 4). However, the absence of MVP does not lead to an
increased activity in any of the MDR-related proteins tested. To
investigate whether the inhibition of MRP1 has more severe conse-
quences for the MVP knockout cells than for the MVP wild-type cells,
the sensitivity to doxorubicin and etoposide in the presence of the
MRP1 modulator MK571 was tested in a MTT assay. Doxorubicin
and etoposide were chosen because these agents are known substrates
Fig. 2. Absence of MVP transcript and protein confirms MVP gene disruption and
results in absence of vault particles. A, Northern blot analysis of total RNA from the liver
of wild-type (/), heterozygous (/), and MVP knockout (/) littermates hybrid-
ized with a MVP antisense RNA probe. The lower panel shows the same blot hybridized
with a control 18 S rRNA probe. B, Western blot analysis of protein lysates from several
tissues from wild-type (/), heterozygous (/), and MVP knockout (/) littermates
for MVP expression. Equal amounts of protein (40 g) were loaded in each lane. C, livers
from wild-type (/) and MVP knockout (/) mice were fractionated to purify vault
particles. Shown are electron micrographs of negatively stained vault preparations that
were obtained from these livers. Vault particles with the typical barrel-shaped morphology
could easily be detected in the wild-type liver fractions, but were absent in the corre-
sponding fractions of the MVP knockout livers. Scale bars correspond to 50 nm.
Fig. 3. Expression of MVP in ES cells and bone marrow (BM) cells. Western blot
analysis of protein lysates from wild-type (/) and MVP knockout (/) ES cells and
bone marrow cells. Equal amounts of protein were loaded in each lane.
Table 1 In vitro cytotoxicity of several cytostatics in MVP/ and MVP/ ES cells
Given are average IC50 values  SD calculated from two to three independent
experiments (n  4–6). Note that some assays were carried out in the presence of 50 M
of the MRP1 inhibitor MK571. No statistically significant differences were observed
between IC50 values in wild-type and knockout cells as determined by the Mann-Whitney
test.
Agent
IC50 (ng/ml)
MVP/ ES cells MVP/ ES cells
Doxorubicin 7.28  1.0 6.15  0.77
Doxorubicin  50 M MK571 3.6  1.0 4.3  0.5
Etoposide 2.38  0.08 2.0  0.08
Etoposide  50 M MK571 1.0  0.08 0.9  0.2
Vincristine 0.86  0.2 0.83  0.053
Methotrexate 11.4  0.58 12.9  2.3
Ifosfamide 466  103  87  103 471  103  35  103
Mitoxantrone 0.53  0.08 0.7  0.2
Gemcitabine 10.05  0.8 10.35  1.1
Taxotere 0.38  0.1 0.30  0.023
Cisplatinum 198  37 228  52
Melphalan 244  71 299  34
Cytosine arabinoside 151  36 244  88
Dexamethason 25  103  211 35  103  1330
Table 2 Inhibition of proliferation of MVP/ and MVP/ bone marrow cells in
response to several cytostatic agents
Presented are the drug concentrations at which proliferation is reduced to 50% as
compared to untreated cells. Given are average values  SD calculated from two
independent experiments (n 4–6). No statistically significant differences were observed
between 50% inhibition values in wild-type and knockout cells as determined by the
Mann-Whitney test.
Agent
Drug concentration (g/ml)
MVP/ bone marrow cells MVP/ bone marrow cells
Doxorubicin 0.131  0.026 0.119  0.027
Etoposide 2.73  1.47 2.84  1.47
Vincristine 0.047  0.008 0.055  0.004
Methotrexate 0.046  0.006 0.039  0.0015
Ifosfamide 2423  270 1991  514
Mitoxantrone 0.0073  0.0016 0.0081  0.0021
Gemcitabine 0.029  0.011 0.0183  0.001
Taxotere 0.0058  0.0006 0.0054  0.0004
Cisplatinum 7.06  2.27 6.23  2.48
Melphalan 5.06  1.19 3.93  1.53
Cytosine arabinoside 0.11  0.02 0.11  0.003
Dexamethason 322  36 326  44
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of MRP1. Although the IC50 values of both doxorubicin and etoposide
were clearly reduced by adding MRP1 inhibitor (Table 1), this effect
was not found to be more pronounced in the MVP-deficient cells.
Toxicity of Doxorubicin in Vivo. Although the disruption of the
MVP gene did not result in an altered sensitivity to drugs in bone
marrow and ES cells, it is possible that MVP/vaults play a role in the
protection of a specific organ. Such an observation was reported for
the P-gp-deficient mice, in which absence of P-gp in the blood-brain
barrier led to accumulation of ivermectin in the brain, resulting in a
100-fold increased sensitivity level to this agent (34). We tested the in
vivo toxicity of doxorubicin in MVP knockout mice, because the
relation between drug resistance and MVP expression was most
obvious for anthracyclines (14, 15). We examined the general appear-
ance, weight loss, and blood cell numbers of 21 wild-type and 23
knockout mice treated with a single i.v. doxorubicin injection of 15
mg/kg bodyweight. The MVP-deficient animals did not show in-
creased symptoms of illness and discomfort when compared with
wild-type control animals. The number of WBCs was slightly de-
creased 3 days after injection in both groups when compared with
noninjected animals, but had recovered in both wild-type and knock-
out mice on day 8 (data not shown). The effects of the doxorubicin
treatment on the bodyweights are presented in Fig. 5. Both MVP/
and MVP/ animals showed loss of weight during the first days after
injection, but the average weight loss was similar in both groups, and
all of the animals were able to stabilize and started to recover their
weights. Furthermore, the damage to organs after injection of 10 mg
doxorubicin/kg bodyweight was investigated extensively, with special
attention to organs that normally exhibit a high expression of MVP.
Effects of the doxorubicin treatment, such as hydropy in the liver and
the disruption of the morphology of the villi in the ileum, were visible
in both knockout and wild-type organs (5 wild-type versus 5 knockout
animals), but the levels of the induced tissue damage were similar
(data not shown).
DISCUSSION
We have successfully generated a MVP knockout mouse. The MVP
mRNA and protein are undetectable in the tissues of the knockout
animals and severely reduced in heterozygous animals. Moreover,
vault particles could no longer be detected in the MVP knockout
tissues.
Both the high degree of evolutionary conservation and the complex
structure of vault particles, as well as its broad distribution in tissues
suggest an important function in cellular processes. Surprisingly, the
MVP knockout animals do not show any obvious abnormalities, breed
normally, and appear healthy. Apparently, vaults do not play an
essential role in the development of mice and in cellular processes in
a normal healthy environment. However, vaults could be involved in
a strategic mechanism needed for survival after induction of cellular
Fig. 5. Effects of doxorubicin treatment on bodyweights of MVP wild-type (WT) and
deficient (KO) mice. Depicted is the average bodyweight of mice i.v. injected with 15
mg/kg doxorubicin, as percentage of the initial bodyweight before treatment; bars,  SD.
Body weights were measured daily after injection of doxorubicin. (  WT,   KO;
n  21 and 23, respectively).
Table 3 Functional expression of P-gp, MRP1, and BCRP in MVP/ and
MVP/ cells
Depicted are the ratios calculated from the intracellular fluorescent substrates in the
absence and presence of the specific modulators PSC 833, MK571, and Ko143. Values
given are averages of two independent experiments.
Bone Marrow ES cells
MVP/ MVP/ MVP/ MVP/
P-gp 1.45 1.51 1.21 0.95
MRP1 10.41 10.48 7.5 8.8
BCRP 1.34 1.09 1.18 1.15
Fig. 4. Functional expression of MDR-related
proteins in wild-type and MVP knockout cells. The
activities of P-gp, MRP1, and BCRP are presented
as the intracellular amounts of Rhodamine-123
(P-gp substrate), DCFDA (MRP1 substrate), or
BODIPY-prazosin (BCRP substrate) in wild-type
(WT) and MVP-deficient (KO) ES cells in presence
(gray plot) or absence (black plot) of the modula-
tors PSC 833, MK571, and Ko143.
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stress or damage. Because the cellular defense against cytotoxic
agents may partly rely on vaults, as was suggested in several clinical
studies and experiments using MDR cell lines, we have examined a
potential function of vaults in multidrug resistance. To this purpose,
two different cell types derived from the MVP knockout model were
tested in two different assays. Firstly, the survival of MVP/ and
MVP/ ES cells, when exposed to different concentrations of cyto-
statics, was examined in a MTT assay. Similar experiments have been
performed in MRP1 deficient ES cells by Lorico et al. (35), who
observed that disruption of MRP1, a MDR-related membrane trans-
port protein, leads to hypersensitivity to etoposide and teniposide and,
to a lesser extent to doxorubicin. Decreased IC50 values of up to 4-fold
were reported. In our experiments, no significant difference in IC50
values and no difference in the survival curves of MVP-deficient and
wild-type ES cells were observed. Secondly, the effects of cytostatic
agents on the proliferative capacity of immature bone marrow cells
isolated from knockout and wild-type littermate animals were exam-
ined in a [3H]thymidine incorporation assay. The inhibition of prolif-
eration in response to all of the administered drugs was similar in
wild-type and MVP-deficient cells. Finally, although more extensive
research using several cytotoxic agents at different concentrations
should be performed to determine the in vivo sensitivity of the MVP
knockout mice, the systemic protection to doxorubicin seems unal-
tered in MVP-deficient mice as compared with the wild-type control
mice. Siva et al. (17) suggested that vaults may be necessary, although
not sufficient for drug resistance. The data presented in this study
confirm these findings, and even suggest that MVP and intact vaults
are not necessary for the resistance to a broad range of anticancer
drugs.
In contrast, in a number of cell line models, MVP expression has
been found to correlate with resistance to several cytostatic agents. A
clear relation between MVP expression levels and resistance to doxo-
rubicin, etoposide, Taxol, and vincristine was reported by Kitazono et
al. (14, 15). Colon cancer SW-620 cells with induced MVP expression
were 6-fold more resistant to doxorubicin, 9-fold to etoposide, 8-fold
to Taxol, and 2-fold to vincristine, as determined by a MTT assay.
When MVP transcript levels were decreased by the expression of
MVP-specific ribozymes, the cells lost the acquired resistance. A
mechanism for the action of MVP/vaults proposed by the authors is
the efflux of doxorubicin from the nucleus. However, because not all
of the drugs investigated in their study have nuclear targets, this only
explains part of the acquired resistance of the SW-620 cells. The
results of these studies also imply that by losing MVP, cells become
more susceptible to doxorubicin, etoposide, and Taxol. However, the
MVP-deficient ES and bone marrow cells used in our study were not
more susceptible to these cytostatic agents or to any other agent tested.
A possible explanation for the unexpected lack of a drug-sensitive
phenotype in the MVP-deficient mice is that vaults only contribute
moderately to drug resistance and that the absence of MVP is com-
pensated for by other MDR proteins, like ABC-transporters such as
P-gp, MRP family members, or BCRP. However, in the MVP-defi-
cient cell systems used in this study, no increase of activity of P-gp,
MRP1, and BCRP was observed. A functional assay showed a con-
siderable activity of MRP1 in both ES cells and bone marrow cells,
but this activity did not change after disruption of MVP. Addition of
a MRP1 inhibitor indeed increased the susceptibility of ES cells for
the MRP1 substrates, doxorubicin and etoposide, but the effects were
identical in MVP wild-type and deficient cells. Hence, it is not likely
that the effects of the disruption of MVP are compensated for by P-gp,
MRP1, or BCRP. However, it cannot be excluded that other ABC-
transporters or unknown mechanisms of drug resistance become up-
regulated on disruption of MVP. Furthermore, our experiments did not
include long-term exposure of cells to low doses of cytostatic agents.
Although a direct involvement of vaults in MDR could not be dem-
onstrated in the MVP knockout mouse model, vaults might still be
involved in the protection against chronic exposure to drugs. On the
other hand, the up-regulation of MVP that has been described in both
in vitro and clinical studies might be a response to cytostatics but not
directly related to the resistance to these agents. Vaults may be
involved in other cellular processes that also become activated on
exposure to toxic agents, such as apoptosis and/or a general stress
response. In addition, some evidence for a role of vaults in cellular
differentiation was given by Schroeijers et al. (36). The observed
up-regulation of vaults during the development of dendritic cells and
the impaired function of dendritic cells treated with antibodies against
MVP suggest that vaults play a role in the development, maturation,
and functioning of dendritic cells. We are currently investigating the
development and antigen-presenting capacity of dendritic cells de-
rived from the MVP knockout mice.
Although the major component of the vault particle is absent, and
vault particles are no longer detected, the remaining components
TEP1, VPARP, and vRNA might still interact and possibly fulfill a
functional role. However, the levels of the additional vault compo-
nents seem to be severely reduced in MVP knockout tissues.4 Besides
the vault-associated fractions of TEP1 and VPARP, also their levels
outside the vault complex, i.e., associated with the telomerase com-
plex and the nuclear portion of VPARP, may be affected by the
disruption of MVP. If this is the case this might indicate a functional
link between vaults and the telomerase complex in addition to the
simple sharing of the TEP1 subunit. Likewise a possible function of
nuclear VPARP in DNA damage repair might also be impaired.
Determination of the levels of the minor vault proteins, their subcel-
lular localization and the mechanism responsible for the decrease in
their concentrations upon MVP disruption could give important clues
on the still unrevealed function of the vault complex.
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